Targeted compounds inhibiting EZH2 have been introduced in cancer therapeutics with promising results in pre-clinical studies as monotherapies or in combination with traditional chemotherapy and are currently under evaluation in phase 1 and 2 clinical trials. The gene discussed is EZH2; the disease is cancer.